InnovaRx Innova Health Strategies
Pricing Sign in

E31.1

Polyglandular hyperfunction

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 8 never code together
E31code
Excludes1
  • ataxia telangiectasia [Louis-Bar] (G11.3)G11.3
  • dystrophia myotonica [Steinert] (G71.11)G71.11
  • pseudohypoparathyroidism (E20.1)E20.1
E31.1code
Excludes1
E20-E35block
Excludes1
  • galactorrhea (N64.3)N64.3
  • gynecomastia (N62)N62
E00-E89chapter
Excludes1
  • transitory endocrine and metabolic disorders specific to newborn (P70-P74)P70-P74

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Instructional notes 1
E00-E89chapter
Notes
  • All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.E05.8E07.0E16-E31E34.-
Index entries leading here 1
  • Hyperfunction
Alongside this code 4 same parent — E31
E31.0 Autoimmune polyglandular failure E31.2 Multiple endocrine neoplasia [MEN] syndromes category E31.8 Other polyglandular dysfunction E31.9 Polyglandular dysfunction, unspecified
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

CMS22HCC23 CMS28HCC51 ESRD21HCC23 ESRD24HCC23 RX08HCC43

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
E31
Block
E20-E35
Siblings
4

Present FY2024–FY2027.